Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1989 Jul;27(7):1453–1455. doi: 10.1128/jcm.27.7.1453-1455.1989

Cross-sectional study of reverse transcriptase-inhibiting antibody as a marker of acquired immune deficiency syndrome.

M Advani 1, D T Imagawa 1, M H Lee 1, K Sano 1, F Morales 1, R T Mitsuyasu 1, R Detels 1
PMCID: PMC267592  PMID: 2475522

Abstract

A cross-sectional study of 128 individuals infected with human immunodeficiency virus type 1 (HIV-1) was conducted to determine the correlation of reverse transcriptase-inhibiting (RTI) antibody to clinical disease. Thirty-two individuals were studied in each of four clinical groups: asymptomatic individuals, those with persistent generalized lymphadenopathy, those with acquired immune deficiency syndrome (AIDS)-related complex, and those with AIDS. Our study showed that 78% of asymptomatic individuals, 53% of those with persistent generalized lymphadenopathy, 50% of those with AIDS-related complex, and only 25% of those with AIDS have RTI antibody. Concurrent measurement of measles antibody level was used as an indicator of the immune status of these individuals. Measles antibody did not decline in persons with clinical disease, but asymptomatic individuals had lower antibody titers, possibly due to hypergammaglobulinemia associated with advanced HIV infection. These results indicate that more HIV-infected asymptomatic individuals than symptomatic individuals have RTI antibody. This suggests either that the RTI antibody level decreases with the progression of disease in HIV infection or that symptomatic individuals do not produce RTI antibody. The presence or absence of RTI antibody can thus be used as a marker of advanced disease.

Full text

PDF
1453

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan J. S., Coligan J. E., Lee T. H., Barin F., Kanki P. J., M'Boup S., McLane M. F., Groopman J. E., Essex M. Immunogenic nature of a Pol gene product of HTLV-III/LAV. Blood. 1987 Jan;69(1):331–333. [PubMed] [Google Scholar]
  2. Chatterjee R., Rinaldo C. R., Jr, Gupta P. Immunogenicity of human immunodeficiency virus (HIV) reverse transcriptase: detection of high levels of antibodies to HIV reverse transcriptase in sera of homosexual men. J Clin Immunol. 1987 May;7(3):218–224. doi: 10.1007/BF00915727. [DOI] [PubMed] [Google Scholar]
  3. DeVico A. L., Veronese F. D., Lee S. L., Gallo R. C., Sarngadharan M. G. High prevalence of serum antibodies to reverse transcriptase in HIV-1-infected individuals. AIDS Res Hum Retroviruses. 1988 Feb;4(1):17–22. doi: 10.1089/aid.1988.4.17. [DOI] [PubMed] [Google Scholar]
  4. Hollis V. W., Jr, Aoki T., Barrera O., Oldstone M. B., Dixon F. J. Detection of naturally occurring antibodies to RNA-dependent DNA polymerase of murine leukemia virus in kidney eluates of AKR mice. J Virol. 1974 Feb;13(2):448–454. doi: 10.1128/jvi.13.2.448-454.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jacquemin P. C., Saxinger C., Gallo R. C., Hardy W. D., Jr, Essex M. Antibody response in cats to feline leukemia virus reverse transcriptase under natural conditions of exposure to the virus. Virology. 1978 Dec;91(2):472–476. doi: 10.1016/0042-6822(78)90393-8. [DOI] [PubMed] [Google Scholar]
  6. Johnson R. B., Jr, Libby R. Separation of immunoglobulin M (IgM) essentially free of IgG from serum for use in systems requiring assay of IgM-type antibodies without interference from rheumatoid factor. J Clin Microbiol. 1980 Sep;12(3):451–454. doi: 10.1128/jcm.12.3.451-454.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Laurence J., Saunders A., Kulkosky J. Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity. Science. 1987 Mar 20;235(4795):1501–1504. doi: 10.1126/science.2435004. [DOI] [PubMed] [Google Scholar]
  8. Lee M. H., Sano K., Morales F. E., Imagawa D. T. Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. J Clin Microbiol. 1987 Sep;25(9):1717–1721. doi: 10.1128/jcm.25.9.1717-1721.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature. 1987 Jun 11;327(6122):473–476. doi: 10.1038/327473a0. [DOI] [PubMed] [Google Scholar]
  10. Sano K., Lee M. H., Morales F., Nishanian P., Fahey J., Detels R., Imagawa D. T. Antibody that inhibits human immunodeficiency virus reverse transcriptase and association with inability to isolate virus. J Clin Microbiol. 1987 Dec;25(12):2415–2417. doi: 10.1128/jcm.25.12.2415-2417.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Temin H. M., Baltimore D. RNA-directed DNA synthesis and RNA tumor viruses. Adv Virus Res. 1972;17:129–186. doi: 10.1016/s0065-3527(08)60749-6. [DOI] [PubMed] [Google Scholar]
  12. Verma I. M. The reverse transcriptase. Biochim Biophys Acta. 1977 Mar 21;473(1):1–38. doi: 10.1016/0304-419x(77)90005-1. [DOI] [PubMed] [Google Scholar]
  13. Wuu K. D., Graves D. C., Ferrer J. F. Inhibition of the reverse transcriptase of bovine leukemia virus by antibody in sera from leukemic cattle and immunological characterization of the enzyme. Cancer Res. 1977 May;37(5):1438–1442. [PubMed] [Google Scholar]
  14. di Marzo Veronese F., Copeland T. D., DeVico A. L., Rahman R., Oroszlan S., Gallo R. C., Sarngadharan M. G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science. 1986 Mar 14;231(4743):1289–1291. doi: 10.1126/science.2418504. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES